Cellebrite DI (NASDAQ:CLBT - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.09 by $0.05, Briefing.com reports. The company had revenue of $106.90 million for the quarter, compared to analyst estimates of $102.06 million. Cellebrite DI had a negative return on equity of 748.06% and a negative net margin of 82.28%. The firm's revenue for the quarter was up 27.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.09 EPS. Cellebrite DI updated its FY 2024 guidance to EPS and its Q4 2024 guidance to EPS.
Cellebrite DI Price Performance
NASDAQ:CLBT traded down $0.18 during midday trading on Friday, reaching $18.61. 1,434,023 shares of the company traded hands, compared to its average volume of 1,148,436. The firm has a market capitalization of $3.83 billion, a price-to-earnings ratio of -12.01, a price-to-earnings-growth ratio of 2.63 and a beta of 1.50. The company has a fifty day moving average price of $17.62 and a 200 day moving average price of $14.29. Cellebrite DI has a twelve month low of $7.22 and a twelve month high of $21.00.
Wall Street Analyst Weigh In
CLBT has been the subject of several recent analyst reports. Lake Street Capital raised their price objective on shares of Cellebrite DI from $13.50 to $17.00 and gave the company a "buy" rating in a research note on Friday, August 16th. Needham & Company LLC lifted their price target on Cellebrite DI from $17.00 to $21.00 and gave the company a "buy" rating in a report on Thursday. JPMorgan Chase & Co. increased their target price on Cellebrite DI from $21.00 to $22.00 and gave the stock an "overweight" rating in a research report on Thursday. TD Cowen boosted their price objective on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock a "buy" rating in a research note on Monday, September 23rd. Finally, Bank of America raised their target price on Cellebrite DI from $13.00 to $17.00 and gave the company a "buy" rating in a report on Friday, August 16th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cellebrite DI has an average rating of "Buy" and an average price target of $20.29.
Check Out Our Latest Stock Report on CLBT
About Cellebrite DI
(
Get Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Further Reading
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
